'Painkillers Market Will Reach $61.6 Billion in 2012' Visiongain Report Predicts

Informations

• Publié par: visiongain
• Nombre de lectures: 12
• Langue: English

Extrait

'Painkillers Market Will Reach $61.6 Billion in 2012' Visiongain Report Predicts

PR Newswire LONDON, September 6, 2012

LONDON,September 6, 2012/PRNewswire/ -- A new report by visiongain predicts that the world market for drugs to relieve pain will reach$61.6 billionfor 2012. That revenue forecast appears in World Pain Relieving Drug Market 2012-2022, published inSeptember 2012. Visiongain is a business information provider based inLondon, UK. The study forecasts that the overall market for pain relieving drugs will grow steadily from 2012 to 2022. The world pain-treating drug market is a high- revenue industry with a high public and healthcare profile. Market growth will be stimulated by rises in disease prevalence, ageing populations and prevalence of cancer, arthritis and diabetes. Growth of the pain treatment market will be stimulated by new drugs and reformulations of existing products from 2012 onwards. The launch of new treatments, including more-efficacious drugs, improved drug delivery and new dosing schedules, will increase revenues. Visiongain believes that increasing public awareness and the development of submarkets such as neuropathic and cancer pain treatment will be crucial to expansion of the industry and market. Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: "Pain is a prevalent condition with huge socio-economic consequences. Many people need pain relief to complete everyday tasks. To achieve more-efficient pain relief, a better understanding of its underlying mechanisms and causes are needed, which, in turn, will lead to more pain therapies being tailored to a specific pain type. The high growth rate of the neuropathic pain market is a good example. Also, drug approvals for neuropathic indications are becoming more frequent. Importantly, the pharma industry has many promising R&D pipeline candidates for pain relief." Visiongain's report shows revenue forecasts to 2022 at overall world market, submarket, product and national level. The study includes OTC (over-the- counter) and Rx (prescription) pain relieving medicines. It forecasts these world-level submarkets:

Narcotics Non-narcotics Neuropathic pain relievers Treatments for migraines Treatments for arthritis.

The investigation predicts revenues of 28 leading drugs in the painkillers market, including Oxycontin ER, Panadol, Lyrica and Zomig. Research, data and analyses cover activities of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other pharmaceutical companies. That report discusses R&D and commercial news, shows research interviews and forecasts revenues in leading national markets. The work analyses the US, Japan, five leading EU countries (the EU5),IndiaandChina.

World Pain Relieving Drug Market 2012-2022 adds to visiongain's range of analytical reports on industries and markets in healthcare. For sample pages, an exec summary and further information concerning the World Pain Relieving Drug Market 2012-2022 please visit: http://www.visiongain.com/Report/867/World-Pain-Relieving-Drug-Market-2012- 2022 Companies listed in the report include: Companies Listed AB Science Abbott Laboratories AcelRx Pharmaceuticals Actavis Acura Pharmaceuticals Allergan Almirall Alpharma ALZA Corporation American Council for Headache Education Amgen Anesiva Aoxing Pharmaceuticals Apotec Apotex Arcion Therapeutics Astellas Pharma AstraZeneca Avanir Pharmaceuticals Bayer BioDelivery Sciences Biogen Idec Biovail Corporation Bristol-Myers Squibb Britannia Pharmaceuticals CeNeS Pharmaceuticals Centocor Ortho Biotech China Aoxing CK Life Sciences Collegium Pharmaceutical CoLucid Pharmaceuticals Dainippon Dara Biosciences Depomed Descartes Therapeutics Dr. Reddy's Laboratories Durect Eisai Eli Lilly Endo Pharmaceuticals EpiCept European Medicines Agency (EMA)

Food and Drug Administration (FDA) Forest Pharmaceuticals Galderma Genentech Genmab GlaxoSmithKline (GSK) Grünenthal Horizon Pharma Human Genome Sciences Insys Therapeutics International Association for the Study of Pain (IASP) Ipsen IVAX Pharmaceuticals Janssen Pharmaceuticals Johns Hopkins University Johnson and Johnson (J&J) King Pharmaceuticals Ligand Pharmaceuticals Lundbeck MAP Pharmaceuticals Merck & Co. Merck Serono Mitsubishi Tanabe Pharma Mylan National Health Service (NHS) National Institute for Health and Clinical Excellence (NICE) Nektar Therapeutics NeurAxon NeurogesX Neurotune Newron Pharmaceuticals NicOx Pharmaceuticals Novartis NuPathe Nuvo Research Omeros Ono Pharmaceutical Organon Ortho-McNeil Pacira Pharmaceuticals Pain Therapeutics Paion Par Pharmaceuticals Penwest Pfizer Pharmacia PLx Pharma Pozen PriCara Pharmaceuticals Procter & Gamble Proteus

Purdue Pharma QRxPharma Ranbaxy Ratiopharm Rigel Pharmaceuticals Roche Schering Plough Shire SkyePharma Solvay Pharmaceuticals Spinifex Pharmaceuticals Stada Pharmaceuticals Sun Pharmaceuticals Syntaxin Takeda Teikoku Teva Pharmaceutical Industries The Arthritis Foundation The International Diabetes Federation (IDF) The Neuropathy Association The World Health Organization (WHO) UCB University of Queensland US Census Bureau US Society for Neuroscience US WorldMeds Valeant Pharmaceuticals International Watson Pharmaceuticals WEX Pharmaceuticals Wyeth (now part of Pfizer) Xenoport Zars Pharmaceuticals Zenyaku Kogyo Zogenix Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to [e-mail] or call her on [phone] About visiongain Visiongain is one of the fastest growing and most innovative independent media companies inEurope. Based inLondon, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e- zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. For an executive summary of this report or to order it today please contact: Email: Sara Peerun on [e-mail], Tel: [phone]